All eyes are now on the leading late COVID-19 vaccine candidates. However, there are other experimental vaccines in development. In which Motley Fool Live The video, recorded on December 3, 2020, discusses two early-stage COVID vaccines by Healthcare and Corean Bureau chief Corinne Cardina and Fool.com author Keith Spides.
Corinne Cardina: Are there any drug developers who are in the early stages rather than certain drugs that take a game-changing approach?
Keith Spites: Yeah, there’s a couple I saw, Corinne.
I think you and I have talked before – Waxard (Nasdaq: VXRT). Vauxhall has an early stage oral tablet. The idea of having a vaccine that makes you pop a pill, so to speak, instead of getting stuck with a needle, would be very puzzling. The lowest market cap there – less than 1 billion. Again, this is the initial stage, but if they are successful, Vauxhall may actually exit.
Another, a little plug here, shameless plug. I am working on an article to be published on Saturday. This is about the dark horse to watch, and the dark horse to watch in the corona virus vaccination race, I think Arthritis treatment (NASDAQ: ARCT).
Arcutter has an MRNA vaccine. Pfizer And Moderna Have MRNA vaccines, so we have already seen that they may have the highest efficacy. But they do have MRNA Single dose Vaccine that is in the 1/2 study at one point.
They also hope to get its freeze-dried version for the Phase 3 test. Check all the boxes and you’re got Arcturus. Single-dose, which would be awesome, MRNA, seems to have the highest performance, and the freeze-dried ones would address some of the cold storage needs. Arcturus is something I was most impressed with. I’m going to see what happens next and see what the results will be.
Corinne Cardina: Keith, do you know the ticker for the artist?
Keith Spites: Yes. It is ARCT.
Corinne Cardina: I learned.
Keith Spites: Again, the best way to describe Arcturus is the dark horse. If things go right they may come out really strong.